Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Medicine for treating psoriasis

A technology for psoriasis and drugs, applied in the field of drugs for the treatment of psoriasis, can solve the problems of complex preparation process and high price, and achieve the effects of good safety, improvement of pathological damage, and wide range of social health needs

Inactive Publication Date: 2016-05-25
THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
View PDF7 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the preparation process is complex and expensive

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicine for treating psoriasis
  • Medicine for treating psoriasis
  • Medicine for treating psoriasis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0020] Embodiment 1: the preparation of the liniment for the treatment of psoriasis

[0021] Drug name: c41 molecule

[0022] The sequence is shown in SEQIDNO: 1, and the modified structure is: T*G*G*C*G*C*G*C*A*C*C*C*A*C*G*G*C*C*T*G , wherein, (* is thio-modified).

[0023] Preparation method: chemical synthesis, entrusted to Shanghai Shenggong Company. Yield, purified by HPLC, vacuumed, stored in glass vials at room temperature, and packaged at 330 μg / vial (dry powder).

[0024] Usage configuration: Take a small bottle, inject 600μl PBS, dilute and mix well, set aside.

Embodiment 2

[0025] .Example 2: Inhibition of activation identification of TLR7 / 8 and 9

[0026] 2.1 Main materials, reagents and equipment:

[0027] 1) Cell line: RAW264.7 (ATCC, USA.).

[0028] 2) Cell culture medium: DMEM (Gibco, Inc., USA).

[0029] 3) Elisa kit: anti-mouse TNF-a (eBioscience, Inc., USA).

[0030] 4) Cell incubator: FORMA3111.

[0031] 5) Microplate reader: full-wavelength multifunctional microplate reader (ThermoScientific, USA).

[0032] 2.2 Experimental method: Dilute RAW264.7 cells to 1×10 6 / mL, added to a 96-well plate (200 μL / well), placed at 37 ° C, 5% CO 2 After culturing in the incubator for 2 hours, the TLR7 / 8 agonist R848 (5 μl, final concentration 100 ng / ml) was added as the experimental group; the TLR9 agonist CpG-ODN18265 μl (5 μl, final concentration 4 μM) was added as the second experimental group. Set 8 multiple wells. Then, each component is divided into 4 multiple wells, and 5 μl of culture solution is added, as a group and two groups of plac...

Embodiment 3

[0034] Example 3: Drugs are applied to treat psoriasis and its curative effect after punching holes with microneedles

[0035] 3.1 Main materials, reagents and equipment:

[0036] 1) Animal: Balb / c (Huafukang Biotechnology Co., Ltd., China).

[0037] 2) Modeling drug: imiquimod (Mingxin Pharmaceutical, China).

[0038] 3) therapeutic drug: liniment of the present invention (see embodiment 1 for details)

[0039] 3.2 Experimental method:

[0040] 1) After the mice were shaved, the psoriasis model was established on the back of the imiquimod, 10mg / cm2, once a day, for 6 days.

[0041] 2) Grouping: placebo group and drug treatment group, each with 5 rats.

[0042] 3) Drug administration channel: use the flywheel microneedle for beauty, and roll it on the skin surface of each mouse.

[0043] 4) Administration: placebo group: smear with phosphate buffered solution (PBS), 200 μl / 20g body weight; treatment group: the C41 drug of the present invention is diluted to 550 μg / ml with...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to a medicine for treating psoriasis. The medicine is prepared from a phosphorothioate modified molecule preparation and phosphate buffer, wherein the phosphorothioate modified molecule preparation is used as the active ingredient and has the sequence shown in SEQ ID NO:1. The medicine can resist activation of TLR7 / 8 and TLR9, restrain release of proinflammatory factors such as TNF and IL, and achieve an inflammation restraining effect. By means of a surface microneedle system, micropores penetrating through a cuticle are established without causing the pain feeling, the medicine smoothly enters affected parts through inunction and is diffused in corium layers, activation of aggregated immune cells is prevented, and the pathological injury by psoriasis can be remarkably relieved.

Description

technical field [0001] The invention belongs to the field of biotechnology, and in particular relates to a medicine for treating psoriasis. Background technique [0002] Psoriasis, commonly known as psoriasis, is a common chronic inflammatory skin disease in clinical practice. It occurs more frequently in young and middle-aged people, with a longer course of disease and easy recurrence. It presents progressive skin lesions and thickened keratin. The clinical manifestations are mainly erythema and scales, and the whole body can be affected. [0003] Although it was early recognized that the disease is an autoimmune disease related to heredity and infection. However, the specific pathogenic mechanism is not clear, so there is no specific drug at present, and non-specific drug treatment is mainly used to soften the stratum corneum as a symptomatic strategy, or a treatment plan that uses a small amount of hormones as an auxiliary treatment. Larger side effects, and unsatisfact...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K38/10A61P17/06
CPCA61K38/10A61K9/0014A61K9/0021
Inventor 李彦祝元峰刘万成郑新川杨雪姣郑江
Owner THE FIRST AFFILIATED HOSPITAL OF THIRD MILITARY MEDICAL UNIVERSITY OF PLA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com